Business Overview: Annovis Bio, Inc. (NYSE American: ANVS)

---

Executive Summary

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company developing disease-modifying therapies for neurodegenerative diseases, most notably Alzheimer's disease and Parkinson's disease. Unlike the amyloid-beta or alpha-synuclein single-target approaches that have dominated the field, Annovis's thesis is that multiple toxic misfolded proteins (amyloid-beta, tau, and alpha-synuclein) share a common upstream driver — dysregulation of axonal transport — and that targeting this shared upstream mechanism can improve both cognitive and functional symptoms across multiple neurodegenerative diseases simultaneously.

Its lead candidate, buntanetap (posiphen), is an oral small molecule designed to inhibit the translation of multiple neurotoxic proteins at once, rather than clearing a single already-formed protein aggregate as most amyloid-targeted antibodies do.

---

1. Core Business Model & How They Work

As a clinical-stage biotech, Annovis Bio does not currently generate meaningful product revenue. Its value chain follows the standard biopharma model:

[ Multi-Target Neuroprotective Mechanism ] ➡️ [ Ph2/3 Trials in Alzheimer's & Parkinson's ] ➡️ [ Regulatory Filing ] ➡️ [ Commercial Launch Across Multiple Neurodegenerative Indications ]

Key Operational Drivers

1. Upstream, Multi-Pathology Mechanism: By targeting the translation of amyloid precursor protein, alpha-synuclein, and tau simultaneously, buntanetap aims to address the "mixed pathology" reality of most real-world Alzheimer's and Parkinson's patients, rather than a single idealized target.
2. Oral, Small-Molecule Convenience: Unlike the infused monoclonal antibodies (e.g., Leqembi, Kisunla) that dominate recently approved Alzheimer's treatment, buntanetap is an oral pill, a potentially significant convenience and access advantage if efficacy is demonstrated.
3. Capital-Intensive Clinical Development: Like all clinical-stage biotechs, Annovis depends on equity financing to fund large, lengthy neurodegenerative disease trials, which require long follow-up periods to demonstrate functional and cognitive benefit.

---

2. Pipeline & Products

---

3. Competitive Landscape

Competitors by Domain

Alzheimer's Disease

• Key Competitors: Biogen/Eisai's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) are the approved, amyloid-plaque-clearing infused antibody standard of care; Eli Lilly, Roche, and others continue to advance additional amyloid and tau-targeted antibodies.
• Dynamics: The approved antibody class has demonstrated modest but real slowing of cognitive decline, alongside meaningful safety concerns (ARIA brain swelling/bleeding) and burdensome infusion/monitoring requirements. Annovis is positioning buntanetap as a potentially safer, more convenient oral alternative or complement if its multi-target mechanism proves effective — but it must still generate pivotal efficacy data that meets the same bar the antibody class has already cleared commercially and regulatorily.

Parkinson's Disease

• Key Competitors: Existing dopaminergic therapies (levodopa/carbidopa and its generics) address symptoms rather than the underlying neurodegeneration; no approved disease-modifying therapy for Parkinson's currently exists, giving Annovis a potential first-mover opportunity if buntanetap proves disease-modifying rather than merely symptomatic.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Differentiated multi-target mechanism: Simultaneously addressing several misfolded proteins implicated in mixed neurodegenerative pathology is scientifically distinct from the single-target antibody approaches dominating the field.
• Oral dosing: A pill-based regimen would avoid the infusion centers, MRI monitoring, and ARIA risk management infrastructure required for the approved antibody therapies, a potentially significant practical advantage.
• Applicability across two large indications: A single mechanism addressing both Alzheimer's and Parkinson's, if validated, would give Annovis two major commercial opportunities from one core asset.

Strategic Risks & Vulnerabilities

1. Single-Asset Concentration Risk: With buntanetap as its only clinical-stage program, any pivotal trial failure would leave Annovis with no near-term backup asset.
   • Mitigation Strategy: Running parallel trials in both Alzheimer's and Parkinson's provides some diversification of clinical risk within the single mechanism.
2. High Historical Failure Rate in Neurodegeneration: Alzheimer's and Parkinson's drug development has one of the highest late-stage failure rates in the industry, and multi-target mechanisms can be harder to validate with clean biomarker endpoints than single-target approaches.
3. Financing Risk: Large, long-duration pivotal neurodegenerative trials are expensive, and continued financing will likely require additional dilutive capital raises.
   • Mitigation Strategy: Potential to pursue partnership or licensing deals with larger pharma to co-fund late-stage trials and eventual commercialization.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Annovis Bio is pursuing one of the more scientifically ambitious bets in neurodegeneration: that a single oral small molecule targeting the shared upstream translational dysregulation behind multiple toxic proteins can succeed where decades of single-target approaches have largely disappointed, while also offering a more convenient and potentially safer dosing profile than the newly approved amyloid antibody class.

The company's future rests almost entirely on buntanetap's pivotal trial results in Alzheimer's and Parkinson's disease — a binary, high-stakes outcome typical of single-asset neuroscience biotechs, where success would open two large commercial markets simultaneously but failure would leave the company with no clinical-stage fallback.